ClinicalTrials.gov
ClinicalTrials.gov Menu

Risperidone for the Treatment of Cocaine Dependence - 7

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000342
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : January 16, 2017
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)

September 20, 1999
September 21, 1999
January 16, 2017
July 1996
August 1997   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00000342 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Risperidone for the Treatment of Cocaine Dependence - 7
Risperidone for the Treatment of Cocaine Dependence
The purpose of this study is to evaluate clinical safety and pharmacological efficacy in the treatment of cocaine dependence, to evaluate impact of treatment on craving, and to correlate evidence of baseline neurotoxic damage of cocaine with treatment outcome and clinical side-effects.
Not Provided
Interventional
Phase 2
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Cocaine-Related Disorders
Drug: Risperidone
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
0
Same as current
September 1997
August 1997   (Final data collection date for primary outcome measure)

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.

Sexes Eligible for Study: All
21 Years to 50 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00000342
NIDA-3-0010-7
Y01-3-0010-7
Not Provided
Not Provided
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
June 1997

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP